Table 2.
Dosage and administration routes of buprenorphine in the pediatric population
Dosage form | Route | Indications | Recommended dose | Age (years) |
---|---|---|---|---|
Injectable solution (0.3 mg buprenorphine hydrochloride) | IV | Premedication Postoperative analgesia |
1.5–3 μg/kg | 3–1777 0.5–615 |
Chronic pain in palliative care Chronic pain |
1–6 μg/kg | >0.518 | ||
PCA | Chronic pain in palliative care Postoperative analgesia |
3 μg/kg (max 150 mg) 6 h | >0.518 | |
CI | Maintenance of mechanical ventilation | 0.72–2.16 μg/kg/h | 27–32 WGA55 | |
Chronic pain in palliative care | 0.5 μg/kg/h (max 30 mg/h) | >0.518 | ||
SC | Pain in palliative care | 0.5 μg/kg/h (max 30 mg/h) | >0.518 | |
Epidural | Postoperative analgesia | 2.5–4 μg/kg | 11.0178 0.5–1279 11–1380 |
|
Sublingual tablets (0.2 mg buprenorphine hydrochloride) | SL | Premedication Chronic pain Postoperative analgesia |
3 μg/kg | 4.8–1581 |
Chronic pain in palliative care | 4–200 μg/kg/8 h | >0.518 | ||
TDS (patch containing 5, 10, 20, 30, or 40 mg buprenorphine) | TDS | Chronic pain in palliative care | Start: 17.5 μg/h End: 35 μg/h |
3–574 |
Start: 8.75 μg/h End: 35 μg/h |
2–1749 | |||
5–15 μg/h | 3–1082 |
Abbreviations: IV, intravenous; PCA, patient-controlled administration; CI, continuous infusion; SC, subcutaneous; SL, sublingual; TDS, transdermal delivery system; WGA, week gestational age; max, single maximal dose at the start of continuous infusion.